Biocon Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Biocon şirketinin toplam hissedar öz sermayesi ₹267.2B ve toplam borcu ₹161.5B olup, bu da borç-öz sermaye oranını 60.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹571.3B ve ₹304.1B dir. Biocon 'in FAVÖK'ü ₹15.9B faiz karşılama oranı 2 dur. Şirketin ₹26.5B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

60.4%

Borç/özkaynak oranı

₹161.50b

Borç

Faiz karşılama oranı	2x
Nakit	₹26.50b
Eşitlik	₹267.20b
Toplam yükümlülükler	₹304.08b
Toplam varlıklar	₹571.28b

Son finansal sağlık güncellemeleri

Recent updates

Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results

Nov 02

Why Investors Shouldn't Be Surprised By Biocon Limited's (NSE:BIOCON) Low P/E

Nov 01

Do Biocon's (NSE:BIOCON) Earnings Warrant Your Attention?

Oct 14

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Sep 20

Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors

Jun 29

Is Biocon (NSE:BIOCON) A Risky Investment?

Jun 11

Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50

Jun 11

Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

May 24

Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50

May 23

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Mar 20

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Feb 12

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Jan 23

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Jan 03

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Nov 13

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Aug 03

Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Jul 03

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 02

Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

May 26

Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Mar 28

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Feb 26

Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate

Dec 17

Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?

Sep 05

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 13

Biocon Limited (NSE:BIOCON) Shares Could Be 20% Below Their Intrinsic Value Estimate

May 26

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BIOCON 'nin kısa vadeli varlıkları ( ₹151.5B ) kısa vadeli yükümlülüklerini ( ₹158.1B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: BIOCON şirketinin kısa vadeli varlıkları ( ₹151.5B ) uzun vadeli yükümlülüklerini ( ₹146.0B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BIOCON 'nin net borç/öz sermaye oranı ( 50.5% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: BIOCON şirketinin borç/öz sermaye oranı son 5 yılda 30.5% seviyesinden 60.4% seviyesine yükseldi.

Borç Kapsamı: BIOCON 'nin borcu işletme nakit akışı ( 25% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: BIOCON 'in borcuna ilişkin faiz ödemeleri EBIT ( 2 x kapsam) tarafından iyi karşılanmıyor.

Biocon Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Is Biocon (NSE:BIOCON) A Risky Investment?

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Recent updates

Consensus EPS estimates fall by 20%

Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results

New major risk - Financial position

Why Investors Shouldn't Be Surprised By Biocon Limited's (NSE:BIOCON) Low P/E

Second quarter 2025 earnings released: ₹0.13 loss per share (vs ₹1.05 profit in 2Q 2024)

Do Biocon's (NSE:BIOCON) Earnings Warrant Your Attention?

Biocon Limited to Report Q2, 2025 Results on Oct 30, 2024

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

High number of new directors

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited to Report Q1, 2025 Results on Aug 08, 2024

Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors

Upcoming dividend of ₹0.50 per share

Biocon Limited Announces Appointment of Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer

Investor sentiment improves as stock rises 18%

Is Biocon (NSE:BIOCON) A Risky Investment?

Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50

Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50

New minor risk - Earnings quality

Dividend of ₹0.50 announced

Biocon Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹5.3m worth of stock

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer

Insider recently sold ₹3.3m worth of stock

Insider recently sold ₹1.1m worth of stock

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Biocon Limited Announces Nehal Vora Resigns as Commercial Head, Effective March 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Investor sentiment improves as stock rises 17%

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Insider recently sold ₹1.8m worth of stock

Biocon Limited Announces the Resignation of Prasad Deshpande as Head SCM and Central Engineering, Senior Management Personnel, Effective January 16, 2024

Biocon Limited Appoints Nicholas Robert Haggar as an Independent Director

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Biocon Limited Announces Management Changes

Insider recently sold ₹13m worth of stock

Group Chief Information Officer recently sold ₹3.2m worth of stock

Biocon Limited Appoints Peter Bains as Biocon Group Chief Executive Officer

Insider recently sold ₹1.6m worth of stock

Consensus EPS estimates fall by 16%

Biocon Limited Approves Appointment of Ms. Rekha Mehrotra Menon as an Independent Director

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Biocon Limited Announces Cessation of Vijay Kumar Kuchroo as a Director

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Insider selling

Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Upcoming dividend of ₹1.50 per share at 0.6% yield

Insider recently sold ₹5.3m worth of stock

Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

Biocon Limited, Annual General Meeting, Aug 11, 2023

Biocon Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 8, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Insider recently sold ₹2.3m worth of stock

Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Insider recently sold ₹1.1m worth of stock

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 17%

Price target decreased by 7.4% to ₹316

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Third quarter 2023 earnings released: ₹0.35 loss per share (vs ₹1.57 profit in 3Q 2022)

Biocon Limited to Report Q2, 2024 Results on Nov 06, 2023

Consensus forecasts updated